BeStock  

United Therapeutics UTHR

US equityMarket cap rank #819Drug Manufacturers - Specialty & Generic
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$832.50M+4.1% YoY
Operating profit$241.30M-38.0% YoY
Net profit$258.60M-23.6% YoY
Diluted EPS$5.71-20.3% YoY
Free cash flow$125.80M-64.2% YoY
Operating cash flow$306.50M

Revenue, last 8 quarters

$735.9MDec '24$794.4MMar '25$798.6MJun '25$799.5MSep '25$790.2MDec '25$781.5MMar '26$783.3MJun '26$832.5MSep '26

Net profit, last 8 quarters

$301.3MDec '24$322.2MMar '25$309.5MJun '25$338.7MSep '25$364.3MDec '25$274.9MMar '26$333.0MJun '26$258.6MSep '26

Diluted EPS by quarter

6.19Dec '246.63Mar '256.41Jun '257.16Sep '257.70Dec '255.82Mar '267.27Jun '265.71Sep '26

Free cash flow by quarter

$254.5MDec '24$386.3MMar '25$129.5MJun '25$351.6MSep '25$167.8MDec '25$362.5MMar '26$205.6MJun '26$125.8MSep '26

Annual revenue

$1.5BFY20$1.7BFY21$1.9BFY22$2.3BFY23$2.9BFY24$3.2BFY25

Profitability & balance sheet

Gross margin86.3%
Operating margin39.4%
Net margin38.6%
Return on equity19.1%
Return on assets17.1%
Return on invested capital17.4%
Current ratio4.61
Liabilities / assets10.8%
Cash & investments$2.07B
Net cash (debt)$2.07B
Free cash flow / sales27.0%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Tyvaso DPI$378.50M 45.5%
  • Orenitram$145.00M 17.4%
  • Nebulized Tyvaso$125.30M 15.1%
  • Remodulin$122.00M 14.7%
  • Unituxin$52.30M 6.3%
  • Other$4.90M 0.6%
  • Adcirca$4.50M 0.5%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $832.50M $783.30M $781.50M $3.18B $790.20M
Total Operating Revenue $832.50M $783.30M $781.50M $3.18B $790.20M
Cost of Revenue $99.10M $99.50M $133.40M $384.40M $103.40M
Gross Profit $733.40M $683.80M $648.10M $2.80B $686.80M
Operating Expense $492.10M $353.00M $322.30M $1.28B $329.30M
Selling and Admin Expenses $212.90M $206.70M $184.10M $731.10M $189.80M
-Selling & Marketing Expense $41.00M $37.30M $28.70M $118.60M $32.70M
-General & Admin Expense $171.90M $169.40M $155.40M $612.50M $157.10M
Research & Development $279.20M $146.30M $138.20M $550.00M $139.50M
Operating Profit $241.30M $330.80M $325.80M $1.52B $357.50M
Net Non-Operating Interest Income (Expense) $30.80M $28.60M $38.80M $172.50M $40.10M
Non-Operating Interest Income $33.70M $31.50M $41.80M $192.00M $43.20M
Non-Operating Interest Expense $2.90M $2.90M $3.00M $19.50M $3.10M
Other Income (Expense) $100.70M $13.30M -$46.30M $24.20M $46.40M
Special Income (Charges) $66.50M $0.00 – -$24.70M -$800,000.00
-Less:Impairment of Capital Assets $0.00 $0.00 – $21.70M $0.00
-Less:Other Special Charges -$66.50M – – $3.00M $800,000.00
Other Non-Operating Income (Expenses) $34.20M $13.30M -$46.30M $48.90M $47.20M
Pretax Profit $372.80M $372.70M $318.30M $1.71B $444.00M
Tax $114.20M $39.70M $43.40M $379.20M $79.70M
Net Profit $258.60M $333.00M $274.90M $1.33B $364.30M
Profit from Continuing Operations $258.60M $333.00M $274.90M $1.33B $364.30M
Net Income to Parent Company $258.60M $333.00M $274.90M $1.33B $364.30M
Net Income to Common Stockholders $258.60M $333.00M $274.90M $1.33B $364.30M
Basic EPS $6.06 $7.82 $6.32 $30.13 $8.41
Diluted EPS $5.71 $7.27 $5.82 $27.86 $7.70

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $7.03B $7.22B $6.71B $7.88B $7.88B
Total Current Assets $2.88B $3.48B $2.87B $3.70B $3.70B
Cash and Cash Equivalents & Short-Term Investments $2.07B $2.66B $2.15B $2.92B $2.92B
-Cash and Cash Equivalents $1.19B $1.80B $1.28B $1.56B $1.56B
-Short Term Investments $879.00M $859.10M $874.00M $1.36B $1.36B
Receivables $348.60M $310.30M $312.00M $350.20M $350.20M
-Accounts Receivable $348.60M $310.30M $312.00M $350.20M $350.20M
Inventory $201.90M $193.80M $178.30M $183.10M $183.10M
Other Current Assets $261.80M $317.30M $228.00M $248.90M $248.90M
Total Non-Current Assets $4.15B $3.74B $3.84B $4.18B $4.18B
Net PPE $2.04B $1.93B $1.84B $1.73B $1.73B
-Gross PPE $2.68B $2.54B $2.43B $2.30B $2.30B
-Accumulated Depreciation -$636.30M -$612.10M -$589.30M -$567.80M -$567.80M
Investments and Advances $1.47B $1.14B $1.32B $1.78B $1.78B
-Available for Sale Securities $1.47B $1.14B $1.32B $1.78B $1.78B
Goodwill and Other Intangible Assets $114.60M $114.10M $115.50M $116.50M $116.50M
Non-Current Deferred Assets $270.20M $311.60M $335.40M $357.70M $357.70M
Other Non-Current Assets $259.40M $239.50M $233.20M $196.90M $196.90M
Total Liabilities $758.10M $819.80M $813.10M $783.80M $783.80M
Total Current Liabilities $624.30M $607.80M $599.10M $560.60M $560.60M
Other Current Liabilities $104.10M $110.00M $100.80M $72.60M $72.60M
Total Non-Current Liabilities $133.80M $212.00M $214.00M $223.20M $223.20M
Other Non-Current Liabilities $133.80M $212.00M $214.00M $223.20M $223.20M
Total Equity $6.28B $6.40B $5.90B $7.10B $7.10B
Stockholders' Equity $6.28B $6.40B $5.90B $7.10B $7.10B
Capital Stock $800,000.00 $800,000.00 $800,000.00 $800,000.00 $800,000.00
-Common Stock $800,000.00 $800,000.00 $800,000.00 $800,000.00 $800,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $3.02B $2.90B $2.52B $2.80B $2.80B
Retained Earnings $9.42B $9.16B $8.83B $8.56B $8.56B
Less: Treasury Stock -$6.14B -$5.64B -$5.44B -$4.26B -$4.26B
Gains/Losses Not Affecting Retained Earnings -$30.30M -$16.20M -$10.20M $900,000.00 $900,000.00
-Goodwill – – – $32.30M $32.30M
-Other Intangible Assets – – – $84.20M $84.20M
Payables – – – $7.10M $7.10M
-Accounts Payable – – – $7.10M $7.10M
Current Accrued Expenses – – – $480.90M $480.90M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $306.50M $313.60M $463.30M $1.56B $346.20M
Net cash flow from continuing operations $306.50M $313.60M $463.30M $1.56B $346.20M
Net Income from Continuing Operations $258.60M $333.00M $274.90M $1.33B $364.30M
Depreciation & Depletion & Amortization $26.40M $24.20M $22.60M $85.60M $22.80M
Deferred Tax $48.50M $25.70M $25.90M $97.70M -$3.20M
Other Non-Cash Items -$11.10M $24.80M $32.00M -$19.70M -$30.20M
Change in Working Capital -$37.70M -$124.10M $12.40M -$106.50M -$43.00M
-Change in Receivables -$38.30M $1.70M $38.20M -$70.90M -$52.50M
-Change in Inventory -$25.60M -$17.70M -$40.10M -$52.60M -$16.50M
-Change in Payables and Accrued Expense $46.70M -$4.00M -$12.70M $97.90M $23.20M
-Change In Other Working Capital -$20.50M -$104.10M $27.00M -$80.90M $2.80M
Net cash flow from investing -$510.60M $87.50M $743.70M -$551.30M -$227.60M
Net Cash Flow from Continuing Investing Activities -$510.60M $87.50M $743.70M -$551.30M -$227.60M
Net PPE Purchase and Sale -$180.70M -$108.00M -$100.80M -$520.50M -$172.90M
Net Business Purchase and Sale $0.00 $0.00 -$25.00M -$55.00M -$25.00M
Net Investment Purchase and Sale -$345.80M $196.20M $875.20M $40.10M -$34.80M
Net Other Investing Changes $15.90M -$700,000.00 -$5.70M -$10.40M $10.60M
Financing Cash Flow -$410.20M $122.40M -$1.48B -$1.15B $98.40M
Net Cash Flow from Continuing Financing Activities -$410.20M $122.40M -$1.48B -$1.15B $98.40M
Net Issuance Payments Of Debt $0.00 $0.00 $0.00 -$300.00M $0.00
Net Common Stock Issuance -$500.80M -$58.80M -$1.50B -$1.02B -$600,000.00
Proceeds from Stock Option Exercised $92.40M $126.30M $73.90M $183.10M $99.00M
Net Other Financing Charges -$1.80M $54.90M -$58.30M -$16.50M $0.00
Ending Cash Balance $1.19B $1.80B $1.28B $1.56B $1.56B
Net Change in Cash -$614.30M $523.50M -$277.40M -$140.10M $217.00M
Beginning Cash Balance $1.80B $1.28B $1.56B $1.70B $1.34B
Free Cash Flow $125.80M $205.60M $362.50M $1.04B $167.80M
Gain/Loss from Continuing Operations – -$13.40M $61.60M – –
Net Intangibles Purchase and Sale – – – -$5.50M $0.00

Discussion

No comments yet — be the first to weigh in on UTHR.

Sign in to join the discussion.

Scroll to Top